CLINICAL TRIAL: INTERFERON BETA-1A AND GLATIRAMIR IN MS

临床试验：干扰素 Beta-1A 和格拉替米尔治疗多发性硬化症

• 批准号: 7951195
• 负责人: Sharon Lynch
• 金额: $ 7.8万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951195
• 关键词: Acetates; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Interferon beta-1a; Interferon-beta1; Multiple Sclerosis; Relapse; Research; Research Personnel; Resources; Source; United States National Institutes of Health; effective therapy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether the combination of interferon beta 1-a and glatiramir acetate is an effective therapy for relapsing-remitting form of Multiple Sclerosis

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是确定干扰素β1-A和乙酸Glatiramir的组合是否是用于复发形式的多发性硬化症的有效疗法